Lineage Cell Therapeutics (XTAE:LCTX) EV-to-EBIT : -6.75 (As of May. 16, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lineage Cell Therapeutics's Enterprise Value is ₪615.95 Mil. Lineage Cell Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₪-91.27 Mil. Therefore, Lineage Cell Therapeutics's EV-to-EBIT for today is -6.75.

The historical rank and industry rank for Lineage Cell Therapeutics's EV-to-EBIT or its related term are showing as below:

XTAE:LCTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.61 Med: -5.22 Max: -1.33
Current: -6.68

During the past 13 years, the highest EV-to-EBIT of Lineage Cell Therapeutics was -1.33. The lowest was -15.61. And the median was -5.22.

XTAE:LCTX's EV-to-EBIT is ranked worse than
100% of 429 companies
in the Biotechnology industry
Industry Median: 9.84 vs XTAE:LCTX: -6.68

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Lineage Cell Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was ₪819.92 Mil. Lineage Cell Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₪-91.27 Mil. Lineage Cell Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -11.13%.

Lineage Cell Therapeutics EV-to-EBIT Historical Data

The historical data trend for Lineage Cell Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics EV-to-EBIT Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-2.73

-8.72

-7.28

-6.38

-6.34

Lineage Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-9.25	-8.58	-6.67	-6.34	-9.60

Competitive Comparison of Lineage Cell Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Lineage Cell Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lineage Cell Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's EV-to-EBIT falls into.

Lineage Cell Therapeutics EV-to-EBIT Calculation

Lineage Cell Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	615.954	/	-91.268
	=	-6.75

Lineage Cell Therapeutics's current Enterprise Value is ₪615.95 Mil.
Lineage Cell Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-91.27 Mil.

Lineage Cell Therapeutics (XTAE:LCTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Lineage Cell Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-91.268	/	819.91964
	=	-11.13 %

Lineage Cell Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was ₪819.92 Mil.
Lineage Cell Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-91.27 Mil.

Lineage Cell Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

LCTX:USA BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.